Lubin Investment · Blog

Haemonetics (HAE): a niche medical compounder the market underprices

2026-06-16 ·

Haemonetics is a niche medical equipment company managing blood and plasma collection and processing. With a perfect quality score, a 21% free cash flow margin, and a low valuation, the stock is worth watching closely despite slightly elevated debt and a 2% revenue decline in FY2026.

What Haemonetics does: blood as medical infrastructure

Haemonetics is one of those companies the general public has never heard of, yet hospitals worldwide cannot function without. The company makes the machines that separate blood into components (plasma, platelets, red cells), the collection equipment in plasma donation centers, and the real-time blood coagulation monitoring systems used in operating rooms. Its flagship TEG platform (thromboelastography) guides transfusions during cardiac and trauma surgery, reducing unnecessary blood loss. In this technical, regulated niche, Haemonetics has virtually no comparable competitor.

Business quality: perfect 10/10 across our fundamental criteria

My framework scores businesses on ten criteria: profitability, revenue and cash growth, balance sheet quality, share buybacks, margin expansion, and capital efficiency. Haemonetics scores a perfect 10/10. Three numbers stand out. A free cash flow margin of 21%: of every $100 in revenue, $21 becomes real available cash after all expenses. Cash ROCE of 24.7%: solid for a company that must invest heavily in manufacturing and R and D. And free cash flow per share growing at 55.2% per year over five years, despite the COVID-era disruptions to the blood supply market.

The moat: long-term contracts and installed equipment

Haemonetics moat rests on two pillars. First: multi-year contracts with hospitals and collection centers. A hospital that has installed TEG machines and trained its surgeons does not switch suppliers easily. These renewal cycles span five to ten years. Second: the installed base and recurring consumables. Haemonetics machines require proprietary consumables (collection kits, reagents) that generate predictable recurring revenue once equipment is in place. This razor-and-blade model creates revenue visibility that is rare in the medical device industry. It explains why cash conversion is exceptional: 2.84x the accounting profit lands as actual cash.

The post-COVID recovery in plasma and blood markets

The human plasma market suffered a major disruption during COVID: donation center volumes dropped 20-30%. Since 2023, the recovery is structural. Global demand for plasma-derived medicines (immunoglobulins, clotting factors) keeps growing at 6-8% per year, driven by aging populations and emerging market expansion. Haemonetics sits at the heart of this supply chain. Q4 FY2026 confirmed the momentum: 4.8% revenue growth, with Plasma and TEG platforms outperforming full-year expectations. FY2027 guidance is positive.

Valuation: what the market is actually pricing

The P/FCF ratio is the stock price divided by the annual free cash flow per share. A P/FCF of 13.3x for Haemonetics means you pay 13 years of today's cash flow to own this business. That is below the 20-30x typical of quality niche medical device companies. At $76.91, the stock trades below our model's recommended buy price of $78.92 (a 2.6% discount). The discount is modest, but the quality-to-price combination looks favorable if the plasma thesis holds. For live valuation data, visit lubin-investment.com/analyse/HAE.

Risks worth watching

Main risk: debt. Net Debt/FCF of 3.54x means it would take over three and a half years of free cash flow to repay the net debt. That is beyond my usual comfort threshold. Revenue visibility from long contracts and recurring consumables mitigates this, but I track this ratio quarterly. Second risk: FY2026 revenues declined 2% (from $1.360B to $1.334B). Haemonetics is in portfolio transformation mode, divesting less profitable segments and refocusing on core Plasma and TEG. This creates short-term top-line volatility. Third: concentration in a technically and regulatorily complex market exposes the company to reimbursement policy risks.

FAQ

What is the TEG platform and why does it matter?

TEG (thromboelastography) is a diagnostic system that measures blood clotting in real time during surgery. It allows surgeons to guide transfusions precisely, minimizing unnecessary blood loss. Haemonetics is the global leader in this highly specialized segment, with virtually no direct competitor at scale.

Why is Haemonetics' debt a point of concern?

The Net Debt/FCF ratio of 3.54x means it would take over three years of free cash flow to clear the net debt. It is elevated, but manageable given the predictability of contractual revenues. It is the only criterion not perfectly green in our analysis, and I monitor its evolution each quarter.

What is the business model of Haemonetics?

A classic razor-and-blade model: Haemonetics sells machines to hospitals and collection centers, then generates recurring revenue from proprietary kits and reagents required to operate them. This creates strong forward revenue visibility, reflected in a cash conversion ratio of 2.84x accounting profit.

Why did Haemonetics revenues decline in FY2026?

Haemonetics is in portfolio transformation mode, divesting lower-margin segments and refocusing on its core Plasma and TEG platforms. This creates temporary top-line pressure. FY2027 guidance is positive, and free cash flow per share continues to grow.

Voir l'analyse HAE sur Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I have analyzed stocks through their fundamentals for several years and invest my own money with this method. I codified it into a tool that judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).